Evidence map›Paper›PMID 40579852›Full record

ArticleAdvanced biology2025

Targeting RAGE with Nanobodies for Molecular Imaging of Cancers and Alzheimer's Disease.

Guangfeng Liang, Fujing Wang, Wei Xiong, Guangwei Shi, Junling Yuan, Yang Li, Hongyan Zhang, Yanmei Xing, Shan Jin, Kongjun Yang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Guangfeng LiangShenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, 518118, China.
Fujing WangDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Wei XiongDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Guangwei ShiDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Junling YuanDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Yang LiDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Hongyan ZhangDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Yanmei XingDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Shan JinShenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, 518118, China.
Kongjun YangShenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, 518118, China.
Zhongliang DaiDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Jichao SunDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.
Zhijie LiDepartment of Geriatrics, Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Centre for Geriatrics, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.ORCID https://orcid.org/0000-0002-5445-7976
Jianhong WangShenzhen Kangning Hospital, Shenzhen Mental Health Center, Shenzhen, 518118, China.

Funding

Guangdong Basic and Applied Basic Research Foundation 2022A1515010943Science and Technology Foundation of Shenzhen City JCYJ20220818102611025;RCYX20210706092040044
6 · The paper itself

Abstract

The receptor for advanced glycation end products (RAGE) is a multifunctional cell surface receptor implicated in aging and the progression of chronic diseases, including cancer and Alzheimer's disease. Its interaction with advanced glycation end products (AGEs) promotes cellular stress and inflammation, underscoring the diagnostic and therapeutic relevance of targeting RAGE. In this study, we explored the potential of nanobodiessingle-domain antibodies known for high specificity, strong affinity, and deep tissue penetrationas molecular tools for RAGE-targeted applications. Using a phage display library, a panel of RAGE-specific nanobodies were isolated and characterized. Binding activity and affinity were evaluated through enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR) assays. Among them, nanobody NbF8 demonstrated the highest affinity and specificity toward RAGE. In vitro, NbF8 selectively bound RAGE-expressing cells, while in vivo imaging in renal carcinoma and Alzheimer's disease mouse models confirmed its targeted accumulation in RAGE-overexpressing tumors and brain tissues. These findings highlight NbF8 as a promising molecular imaging agent for RAGE-associated diseases. This study supports the potential of RAGE-targeting nanobodies in both diagnostic imaging and therapeutic development, offering a novel approach for precision medicine in conditions driven by RAGE signaling.

Indexed as

Alzheimer DiseaseMolecular ImagingNeoplasmsReceptor for Advanced Glycation End ProductsSingle-Domain AntibodiesAnimalsCell Line, TumorHumansMiceReceptor for Advanced Glycation End ProductsSingle-Domain AntibodiesAlzheimer's diseasein vivo imagingmolecular diagnosticsnanobodiesRAGE (Receptor for Advanced Glycation End Products)renal carcinoma

Identifiers

PMID40579852
PMCPMC12517322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.